Agilent Technologies (A) has entered into a co-marketing agreement with Wasatch BioLabs to accelerate the adoption of Wasatch's Direct Targeted Methylation Sequencing platform, Wasatch said Friday.

The collaboration combines Agilent's SureSelect for genomic DNA and Avida for cell-free DNA with Wasatch's native-read workflow to expand access to targeted sequencing and expedite the development of cost-efficient assays for research, according to a statement.

The companies will offer scientific information, educational programming, and technology demonstrations through 2027, Wasatch said.

Price: 138.15, Change: +1.25, Percent Change: +0.91